Previous close | 0.3560 |
Open | 0.3410 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's range | 0.3325 - 0.3583 |
52-week range | 0.2320 - 3.6800 |
Volume | |
Avg. volume | 145,758 |
Market cap | 2.283M |
Beta (5Y monthly) | 0.87 |
PE ratio (TTM) | N/A |
EPS (TTM) | -2.6700 |
Earnings date | 16 May 2024 - 20 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 1.50 |
MIAMI, April 02, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 69th Emerging Growth Conference on April 3 & 4, 2024. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting compani
MIAMI, Feb. 06, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 67th Emerging Growth Conference on February 7 & 8, 2024. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting compa
Dermata (DRMA) announces reaching an agreement with the FDA to begin a late-stage pivotal clinical program for its acne treatment candidate, DMT310. The stock rises 7%.